In a bid to enhance its operational efficiency, the U.S. Food and Drug Administration (FDA) has unveiled significant upgrades to its systems. These advancements include the introduction of a state-of-the-art artificial intelligence tool and the integration of various data platforms into one cohesive system.
The FDA recently introduced Elsa 4.0, the newest iteration of its AI tool, which is now accessible to all personnel, from scientific reviewers to investigators. According to officials, this upgrade aims to streamline processes and alleviate administrative challenges.
Additionally, the agency has amalgamated over 40 disparate applications and submission systems into a singular platform called HALO, which stands for Harmonized AI & Lifecycle Operations for Data. This integration is designed to enhance employees’ ability to access and analyze information efficiently, eliminating the need to manually transfer documents between different systems.
“Elsa’s enhanced capabilities reinforce the FDA’s commitment to being at the forefront of AI tool deployment that empowers our staff,” stated FDA Commissioner Marty Makary, M.D., M.P.H., in a news release. “By alleviating tedious tasks, we enable our team to concentrate more on their scientific work, resulting in more efficient and fulfilling workflows. Our scientists are among the best in the world, and it is imperative that we support them well.”
Officials revealed that ongoing efforts are being made to integrate Elsa directly with the HALO platform, allowing staff to query data and develop workflows seamlessly within the system. This consolidation is anticipated to broaden AI utilization throughout the agency.
“With the streamlining of our application and submission data sources into HALO, along with improvements in Elsa’s features, Elsa is set to become the primary gateway into the FDA’s systems and data. In the past, FDA staff would provide data to Elsa; however, now Elsa will interface directly with our data,” explained Chief AI Officer Jeremy Walsh. “Incorporating AI into our workflows is a top priority that will enable us to advance regulatory science rapidly and facilitate quicker delivery of effective treatments and cures to patients.”
The Office of Digital Transformation at the FDA has continued to enhance the system since the release of Elsa 1.0 in June 2025, which was accomplished ahead of schedule and within budget.
New features in Elsa 4.0 include customizable agents, document generation, data analysis and visualization tools, secure web search capabilities, voice-to-text dictation, and the conversion of scanned documents into searchable text. Additionally, the system includes improved chat functions and enhanced search tools for extensive document collections.
The FDA assured that Elsa functions within a secure, high-level cloud environment and does not train on sensitive data or information from regulated industries. Expert personnel remain actively involved in all phases of the AI process, overseeing inputs, analysis, and outputs.
This modernization initiative represents a significant step forward in the FDA’s ongoing efforts to employ innovative technologies that enhance scientific research and ultimately benefit patient care.
